Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Mepolizumab and Reslizumab in Healthy Subjects
NCT04183192Phase 1Completed
- Sponsor
- Food and Drug Administration
- Start
- Feb 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mepolizumab and reslizumab in asthma (9 arms), sponsored by Food and Drug Administration. Primary endpoints: Area Under Effect Curve for Eosinophils and Maximum Change From Baseline for Eosinophils. Started Feb 2020; status: completed.
02
Drugs
mepolizumabreslizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04183192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183192.